Skip Navigation

Annals of Oncology 2005 16(10):1565-1566; doi:10.1093/annonc/mdi328
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boyle, P.
Right arrow Articles by Dresler, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boyle, P.
Right arrow Articles by Dresler, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Editorial

Preventing the lung cancer epidemic

P. Boyle* and C. Dresler

International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France

* E-mail: boyle@iarc.fr

The first 10% of the full text of this article appears below.

There are approximately 11 million new cases of cancer diagnosed worldwide each year [1Go] of which one in eight is a lung cancer. Over one million people die from lung cancer each year. In Europe, in 2004, there were approximately 3 million new cases of cancer and 1.7 million deaths from cancer [2Go]. Lung cancer was the commonest incident form of cancer (375 000 new cases) and the commonest cause of death from cancer (340 000 deaths). . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. V. Heymach, L. Paz-Ares, F. De Braud, M. Sebastian, D. J. Stewart, W. E.E. Eberhardt, A. A. Ranade, G. Cohen, J. M. Trigo, A. B. Sandler, et al.
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 20, 2008; 26(33): 5407 - 5415.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
U. Montes, L. M. Seijo, A. Campo, A. B. Alcaide, G. Bastarrika, and J. J. Zulueta
Factors determining early adherence to a lung cancer screening protocol
Eur. Respir. J., September 1, 2007; 30(3): 532 - 537.
[Abstract] [Full Text] [PDF]